Implementation of the prostate cancer prevention trial (PCPT)

被引：23

作者：

Goodman, PJ

Tangen, CM

Crowley, JJ

Carlin, SM

Ryan, A

Coltman, CA

Ford, LG

Thompson, IM

机构：

[1] SW Oncol Grp, Operat Off, San Antonio, TX 78245 USA

[2] SW Oncol Grp, Ctr Stat, Seattle, WA 98109 USA

[3] Natl Canc Inst, Clin Res, Bethesda, MD USA

[4] San Antonio Canc Inst, San Antonio, TX USA

[5] Univ Texas, Hlth Sci Ctr, Div Urol, San Antonio, TX USA

来源：

CONTROLLED CLINICAL TRIALS | 2004年 / 25卷 / 02期

关键词：

study organization; study management; chemoprevention; prostate cancer; finasteride;

D O I：

10.1016/j.cct.2003.11.007

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：203 / 222

页数：20

共 17 条

[1] SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN [J].

BRAWER, MK ;

CHETNER, MP ;

BEATIE, J ;

BUCHNER, DM ;

VESSELLA, RL ;

LANGE, PH .

JOURNAL OF UROLOGY, 1992, 147 (03) :841-845

[2]

BRAWLEY OW, 1994, CANCER EPIDEM BIOMAR, V3, P177

[3] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].

CARTER, HB ;

PEARSON, JD ;

METTER, J ;

BRANT, LJ ;

CHAN, DW ;

ANDRES, R ;

FOZARD, JL ;

WALSH, PC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220

[4] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].

CATALONA, WJ ;

SMITH, DS ;

RATLIFF, TL ;

DODDS, KM ;

COPLEN, DE ;

YUAN, JJJ ;

PETROS, JA ;

ANDRIOLE, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161

[5] PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN [J].

COONER, WH ;

MOSLEY, BR ;

RUTHERFORD, CL ;

BEARD, JH ;

POND, HS ;

TERRY, WJ ;

IGEL, TC ;

KIDD, DD .

JOURNAL OF UROLOGY, 1990, 143 (06) :1146-1154

[6] DESIGN OF THE PROSTATE-CANCER PREVENTION TRIAL (PCPT) [J].

FEIGL, P ;

BLUMENSTEIN, B ;

THOMPSON, I ;

CROWLEY, J ;

WOLF, M ;

KRAMER, BS ;

COLTMAN, CA ;

BRAWLEY, OW ;

FORD, LG .

CONTROLLED CLINICAL TRIALS, 1995, 16 (03) :150-163

[7]

GORMLEY G, 1992, J CELL BIOCH S H, V6, P113

[8] THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].

GORMLEY, GJ ;

STONER, E ;

BRUSKEWITZ, RC ;

IMPERATOMCGINLEY, J ;

WALSH, PC ;

MCCONNELL, JD ;

ANDRIOLE, GL ;

GELLER, J ;

BRACKEN, BR ;

TENOVER, JS ;

VAUGHAN, ED ;

PAPPAS, F ;

TAYLOR, A ;

BINKOWITZ, B ;

NG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1185-1191

[9] CHEMOPREVENTION [J].

GREENWALD, P ;

KELLOFF, G ;

BURCHWHITMAN, C ;

KRAMER, BS .

CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (01) :31-&

[10] THE EFFECT OF FINASTERIDE ON PROSTATE-SPECIFIC ANTIGEN IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].

GUESS, HA ;

HEYSE, JF ;

GORMLEY, GJ .

PROSTATE, 1993, 22 (01) :31-37

← 1 2 →